Found­ing NewLink CEO Charles Link is out; Chi-Med lines up two more drug fil­ings

→ Four years ago NewLink’s shares were rid­ing high on the promise of IDO in on­col­o­gy, trad­ing at more than $50 a share. But as en­thu­si­asm for the field plum­met­ed on the back of some key set­backs, so did the stock. And to­day — with the mar­ket cap sit­ting at $59 mil­lion and the stock open­ing at $1.59 — their found­ing CEO, Charles Link, has hit the ex­it. The biotech will be head­ed by a com­mit­tee dur­ing the tran­si­tion, with CFO Carl Lan­gren join­ing CMO Eu­gene Kennedy, gen­er­al coun­sel Brad Pow­ers and Lori Law­ley, the VP of fi­nance.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER